Author： Alvarez Ricardo
Publisher： Springer Publishing Company
ISSN： 1340-6868
Source： Breast Cancer, Vol.20, Iss.2, 2013-04, pp. : 103-110
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The introduction of trastuzumab into clinical practice changed the natural course of HER2-positive breast cancer. Currently, treatment with trastuzumab represents the standard of care for HER2-positive breast cancer and this treatment has been approved in the adjuvant, neoadjuvant, and metastatic settings. Besides trastuzumab, two other anti-HER2 agents-lapatinib and pertuzumab-have been approved for the treatment of HER2-positive advanced breast cancer. Strong biologic data support the concept of dual HER2 blockade, with different anti-HER2 agents demonstrating complementary mechanisms of action. Several neoadjuvant and metastatic studies performed in HER2-positive breast cancer using dual HER2 blockade have been proven to outperform anti-HER2 monotherapies. These dual combinations of agents represent a promising therapeutic strategy that is now reaching clinical practice. In this review we describe the results of studies utilizing dual blockade in patients with HER2-positive breast cancer.
Related content
Access to resources
Recommend
By Lin Nancy Freedman Rachel Ramakrishna Naren Younger Jerry Storniolo Anna Bellon Jennifer Come Steven Gelman Rebecca Harris Gordon Henderson Mark MacDonald Shannon Mahadevan Anand Eisenberg Emily Ligibel Jennifer Mayer Erica Moy Beverly Eichler April Winer Eric
Breast Cancer Research and Treatment, Vol. 142, Iss. 2, 2013-11 ,pp. :